RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of ABUS
Powered by GPT-4o
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Arbutus Biopharma Corporation stock downgraded from Strong Buy Candidate to Buy Candidate after Friday trading session.
(Updated on Jul 12, 2024)

Buy candidate since Jul 08, 2024 Gain 10.12% PDF

The Arbutus Biopharma Corporation stock price gained 2.28% on the last trading day (Friday, 12th Jul 2024), rising from $3.51 to $3.59. It has now gained 5 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 3.99% from a day low at $3.51 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 15.81% over the past 2 weeks. Volume fell on the last day by -412 thousand shares and in total, 833 thousand shares were bought and sold for approximately $2.99 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 18.58% during the next 3 months and, with a 90% probability hold a price between $3.68 and $4.60 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

ABUS Signals & Forecast

The Arbutus Biopharma Corporation stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $3.35 and $3.24. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, June 05, 2024, and so far it has fallen -1.10%. Further fall is indicated until a new bottom pivot has been found.

Support, Risk & Stop-loss for Arbutus Biopharma Corporation stock

On the downside, the stock finds support just below today's level from accumulated volume at $3.41 and $3.09. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Arbutus Biopharma Corporation finds support just below today's level at $3.41. If this is broken, then the next support from accumulated volume will be at $3.09 and $2.97.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.140 between high and low, or 3.99%. For the last week, the stock has had daily average volatility of 4.25%.

The Arbutus Biopharma Corporation stock is extremely overbought on RSI14 (86). This increases the short-term risk substantially.

Our recommended stop-loss: $3.46 (-3.57%) (This stock has medium daily movements and this gives medium risk. The RSI14 is 86 and this increases the risk substantially. There is a sell signal from a pivot top found 56 days ago.)

Trading Expectations (ABUS) For The Upcoming Trading Day Of Monday 15th

For the upcoming trading day on Monday, 15th we expect Arbutus Biopharma Corporation to open at $3.58, and during the day (based on 14 day Average True Range), to move between $3.47 and $3.71, which gives a possible trading interval of +/-$0.124 (+/-3.44%) up or down from last closing price. If Arbutus Biopharma Corporation takes out the full calculated possible swing range there will be an estimated 6.89% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $3.63 (1.11%) than the support at $3.41 (5.01%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Arbutus Biopharma Corporation stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Arbutus Biopharma Corporation stock to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Strong Buy to a Buy candidate.

Current score: 3.971 Buy Candidate Downgraded

Predicted Opening Price for Arbutus Biopharma Corporation of Monday, July 15, 2024

Fair opening price July 15, 2024 Current price
$3.58 ( 0.186%) $3.59

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for ABUS

Fibonacci Support & Resistance Levels

Level Price
R3 3.72 3.71%
R2 3.67 2.22%
R1 3.64 1.30%
Price 3.59
S1 3.53 -1.68%
S2 3.50 -2.60%
S3 3.44 -4.09%

Accumulated Volume Support & Resistance Levels

Level Price
R3 0 -
R2 0 -
R1 3.63 1.11%
Price 3.59
S1 3.41 -5.01%
S2 3.09 -13.93%
S3 2.97 -17.27%

FAQ

What is the symbol for Arbutus Biopharma Corporation Stock and on which exchange is it traded?
The symbol for Arbutus Biopharma Corporation is ABUS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Arbutus Biopharma Corporation Stock?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Arbutus Biopharma Corporation stock to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Strong Buy to a Buy candidate.

How to buy Arbutus Biopharma Corporation Stock?
Arbutus Biopharma Corporation Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Arbutus Biopharma Corporation Stock.

What's the current price of Arbutus Biopharma Corporation Stock?
As of the end of day on the Jul 12, 2024, the price of an Arbutus Biopharma Corporation (ABUS) share was $3.59.

What is the 52-week high and low for Arbutus Biopharma Corporation Stock?
The 52-week high for Arbutus Biopharma Corporation Stock is $3.65 and the 52-week low is $1.69.

What is the market capitalization of Arbutus Biopharma Corporation Stock?
As of the Jul 12, 2024, the market capitalization of Arbutus Biopharma Corporation is 677.494M.

When is the next earnings date for Arbutus Biopharma Corporation?
The upcoming earnings date for Arbutus Biopharma Corporation is Aug 01, 2024.
Click to get the best stock tips daily for free!

About Arbutus Biopharma Corporation

Arbutus Biopharma Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ... ABUS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT